Email ID
Password
Scrip   
FDA expands label for GlaxoSmithKline's antiepileptic Lamictal XR
02 February 2010
Asher Mullard

The US FDA has expanded the label of GlaxoSmithKline's once-daily Lamictal XR (lamotrigine) extended release tablets to include add-on treatment of epilepsy in patients aged 13 years and older with primary generalized tonic-clonic seizures.

The once-daily voltage-gated sodium channel inhibitor...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36